Business
Multi-Target Metabolic Therapies Creating New Momentum in the Triple Agonist Drug Market
The global triple agonist (GLP-1/GIP/Glucagon) drug market size was valued at USD 2.68 billion in 2025and is expected to reach USD 10.42 billion by 2033, at a CAGR of 18.50% during the forecast period
GLP-1 drugsmetabolic disorder treatmentobesity treatment drugstriple agonist therapyweight loss therapeutics
READ ARTICLE